This year’s edition of @MedTechCon, hosted by @AdvaMedUpdate at the Boston Convention & Exhibition Center will be the best yet! Join us for four days of insights, discussion and connection with leading experts. Here's where you can find us next week👇 #MedTechCon# #MedTech#

Johnson & Johnson Q3 26 Earnings: - Adj EPS: $2.59 (est $2.52) - Sales: $25.40B (est $25.4B) - Medicine Rev: $16.76B (est $16.59B) - Darzalex Rev: $4.24B (est $4.31B) - Tremfya Rev: $2.40B (est $2.21B) - MedTech Sales: $8.64B (est $8.77B) - Sees FY Sales: $101B To $101.4B (est $100.8B To $101.4B) - Sees FY Adj EPS: $11.05 To $11.15 (est $10.96 To $11.11) - Sees FY Adj Oper EPS: $10.95 To $11.05 (est $10.86 To $11.01) - CFO Says Leaning Toward Orthopaedic Unit Spinoff Instead Of Sale

Johnson & Johnson Q3 26 Earnings: - Adj EPS: $2.59 (est $2.52) - Sales: $25.40B (est $25.4B) - Medicine Rev: $16.76B (est $16.59B) - Darzalex Rev: $4.24B (est $4.31B) - Tremfya Rev: $2.40B (est $2.21B) - MedTech Sales: $8.64B (est $8.77B) - Sees FY Sales: $101B To $101.4B (est $100.8B To $101.4B) - Sees FY Adj EPS: $11.05 To $11.15 (est $10.96 To $11.11) - Sees FY Adj Oper EPS: $10.95 To $11.05 (est $10.86 To $11.01) - CFO Says Leaning Toward Orthopaedic Unit Spinoff Instead Of Sale

When time is limited, let us bring the most relevant discussions in the surgical community to you. MedTech Insights is your source for the latest articles and shared points of view. From the rise of surgical intelligence to the rise of colorectal cancer rates in young people, explore the content and conversations that matter most.
 Explore articles at the link: ​

Just like the leaves, we're going red this fall. 🍁 On October 1st, we're rebranding from Shockwave Medical to Johnson & Johnson MedTech and our portfolio will be known as circulatory restoration solutions. Our safe, effective technology will still be called #ShockwaveIVL#, and our product names — like #ShockwaveC2Aero# — are staying the same.

Same spark, new shade of bold. On October 1st, we'll officially shift from Shockwave Medical blue to Johnson & Johnson MedTech red and you'll start to see our entire portfolio referred to as circulatory restoration solutions. Our calcium-cracking technology will still be known as #ShockwaveIVL# and our product names — like #ShockwaveC2Aero# — won't be changing.

Feb 2022: Top 10 #Technology#, #Startup# & #Innovation# Tweets #AI# #ML# #DL# #Flutter# #Python# #R# #WomenWhoCode# #100DaysOfCode# #Coding# #CyberSecurity# #InfoSec# #DataScience# #SQL# #3D# #5G# #IoT# #AR# #VR# #Drone# #Robotics# #SelfDriving# #AV# #EV# #MedTech# #FinTech# #Cloud#

Addressing one of biggest remaining challenges in calcium modification today, NODULE-SHOCK adds a significant chapter in the nodular evidence compendium with excellent outcomes in both arms, as well as represents the first peer-reviewed, published data highlighting the benefits of the more deliverable #ShockwaveC2Aero#, which was associated with a low use of guide extension support (9%) in the calcified nodule arm. Thank you, Dr. @DoctorKini for presenting this important investigator-led research at #TCT2026#. Johnson & Johnson MedTech is committed to supporting research like NODULE-SHOCK that improves our understanding of the role of #ShockwaveIVL# in your treatment algorithm in even the most difficult-to-treat lesions. Learn more in @JACCJournals: US Rx only. Safety info: Product availability may vary by country.